Can Fite Biofarma (XTAE:CANF) 3-Year FCF Growth Rate : 42.10% (As of Dec. 2023)

View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma 3-Year FCF Growth Rate?

Can Fite Biofarma's Free Cash Flow per Share for the three months ended in Dec. 2023 was ₪0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 42.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 45.80% per year. During the past 10 years, the average Free Cash Flow per Share Growth Rate was 36.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 13 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Can Fite Biofarma was 53.10% per year. The lowest was -14.10% per year. And the median was 22.10% per year.

Competitive Comparison of Can Fite Biofarma's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Can Fite Biofarma's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Can Fite Biofarma's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Can Fite Biofarma's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Can Fite Biofarma's 3-Year FCF Growth Rate falls into.

Can Fite Biofarma 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

Can Fite Biofarma (XTAE:CANF) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.

Can Fite Biofarma 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Can Fite Biofarma's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Can Fite Biofarma (XTAE:CANF) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » 3-Year FCF Growth Rate

Comparable Companies

Traded in Other Exchanges

CANF:USA

Address

10 Bareket Street, Kiryat Matalon, P.O. Box 7537, Petah-Tikva, ISR, 4951778

Website

http://www.canfite.com

Can Fite Biofarma Ltd is an advanced clinical stage drug development company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The company's lead drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).